共 80 条
[1]
Yeung C(2014)The health economics of bladder cancer: an updated review of the published literature Pharmacoeconomics. 32 1093-1104
[2]
Dinh T(2006)Clinical model of lifetime cost of treating bladder cancer and associated complications Urology. 68 549-553
[3]
Lee J(2017)Guideline of guidelines: non-muscle-invasive bladder cancer BJU Int 119 371-380
[4]
Avritscher EB(2017)EAU guidelines on non-muscle-invasive Urothelial carcinoma of the bladder: update 2016 Eur Urol 71 447-461
[5]
Cooksley CD(2018)Guideline of guidelines: asymptomatic microscopic haematuria BJU Int 121 176-183
[6]
Grossman HB(2010)Evidence-based clinical practice guidelines for bladder cancer (summary - JUA 2009 Edition) Int J Urol 17 102-124
[7]
Woldu SL(2017)Treatment of non-metastatic muscle-invasive bladder Cancer: AUA/ASCO/ASTRO/SUO guideline J Urol 198 552-559
[8]
Bagrodia A(2016)Diagnosis and treatment of non-muscle invasive bladder Cancer: AUA/SUO guideline J Urol 196 1021-1029
[9]
Lotan Y(2019)Comparison of the harms, advantages, and costs associated with alternative guidelines for the evaluation of hematuria JAMA Intern Med 179 1352-1362
[10]
Babjuk M(2019)Overuse of Cystoscopic surveillance among patients with low-risk non-muscle-invasive bladder Cancer - a National Study of patient, provider, and facility factors Urology. 131 112-119